IPO Step-Ups: Services all the way
This article was originally published in Start Up
Judging by the returns to private investors, service companies win hands-down over drugs and devices.
You may also be interested in...
A group of private enterprises are working to revive the moribund IPO market for venture-backed start-ups.
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.